Navigation Links
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium

Genasense Plus Temodar(R) and Abraxane(R) Show Promising Early Clinical


BERKELEY HEIGHTS, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) today announced the presentation of clinical data using the Company's lead oncology drug, Genasense(R) (oblimersen sodium) Injection in combination with Abraxane(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound; Abraxis BioScience, Inc.) and Temodar(R) (temozolomide; Schering Plough, Inc.) in patients with advanced metastatic melanoma. The study represents the rapid translation of preclinical results that demonstrated marked anticancer synergy with this drug combination. The results will be presented by Dr. Anna C. Pavlick, New York University School of Medicine, at the Chemotherapy Foundation Symposium XXV, entitled "Innovative Cancer Therapy for Tomorrow", at the Marriott Hotel, New York, NY on November 9, 2007.

To date, 8 patients have been accrued to this trial. Of the first 7 evaluable patients, 5 patients have demonstrated clinical benefit, including 3 partial responses that occurred after the first treatment cycle, which have lasted for 40, 24 and 16 weeks, respectively. Two other patients have maintained stable disease lasting for a minimum of 24 weeks. Two patients had progressive disease, and one patient is too early to evaluate. There have been no episodes of Grade 4 (i.e., life-threatening) side-effects. Four patients experienced Grade 3 leukopenia (i.e., reduction in white blood cell count), and 1 patient had Grade 3 thrombocytopenia (i.e., reduction in platelet count).

"Our goal with this trial is to evaluate the synergy of Genasense with drugs other than dacarbazine that are currently used for treatment of patients with advanced melanoma," commented Dr. Pavlick. "Genasense has already demonstrated significant benefit when combined with dacarbazine, and we are pleased to be participating in the confirmatory AGENDA trial. The early data from our new 3-drug study are highly encouraging, and we hope to extend these observations by incorporating the brief IV infusion schedule for Genasense that has recently been developed. This new regimen may offer an active, safe, and convenient treatment for patients with this devastating disease."

The activity of this triple drug combination is supported by preclinical data that were presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. These data can be accessed at: &CI D=43&SHID=&COID

Results from the previous randomized trial of Genasense plus dacarbazine can be accessed at:

About AGENDA: A randomized Phase 3 trial of Genasense in advanced melanoma

The AGENDA This trial seeks to confirm the effectiveness and safety of the Genasense/dacarbazine combination in patients who had the greatest benefit in a preceding randomized trial. AGENDA will enroll approximately 300 patients at sites in North America, Europe and Australia using a biomarker that has been confirmed as a powerful indicator of outcome. More information about AGENDA can be accessed at:

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients for a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed an oral formulation of the active ingredient in Ganite that is currently undergoing initial clinical trials as a potential treatment for diseases associated with accelerated bone loss. Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at:

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

* the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

* the safety and efficacy of the Company's products or product


* the Company's assessment of its clinical trials;

* the commencement and completion of clinical trials;

* the Company's ability to develop, manufacture, license and sell its

products or product candidates;

* the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

* the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

* the adequacy of the Company's patents and proprietary rights;

* the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such


* the Company's ability to retain compliance with the NASDAQ's listing

qualifications; and

* the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.


Brian Korb

The Trout Group


SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
6. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased ... technical presentations offered in symposia, oral sessions, workshops, awards, and posters. The ... range of applications such as, but not limited to, biotechnology, biomedical, drug discovery, ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
Breaking Biology News(10 mins):